The CD-47 targeting therapeutics market is estimated to be worth USD 7.1 billion in 2035

Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD-47 as an effective biomarker for the diagnosis and treatment purposes

Roots Analysis is pleased to announce the publication of its recent study, titled, “CD-47 Targeting Therapeutics Market, 2021-2035.”

The report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of CD47 targeting therapeutics in the healthcare industry, over the next 15 years. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

Leave a Reply